Table 2.
Treatment characteristics and secretory status of the study cohort.
| Treatment Lines | |
|---|---|
| median, N (range) | 4 (3–8) |
| ≤4 lines, N (%) | 72 (55) |
| >4 lines, N (%) | 58 (45) |
| Stem cell transplantation (63 patients) | |
| single ASCT, N (%) | 32 (51) |
| double ASCT, N (%) | 21 (33) |
| ASCT + Allogeneic, N (%) | 10 (16) |
| Paraprotein (isotype) | |
| secreting, N (%) | 130 (100) |
| IgG-heavy chain, N (%) | 97 (75) |
| IgA-heavy chain, N (%) | 18 (14) |
| Secretion type (130 patients) | |
| normo-secretory, N (%) | 106 (82) |
| oligo-secretory, N (%) | 9 (7) |
| micromolecolar, N (%) | 15 (11) |
| Normo-secretory to unmeasurable switch (106 patients) | |
| no switch | 77 (72) |
| oligo-secretory switch after ≤3 lines | 17 (16) |
| oligo-secretory switch after >3 lines | 4 (4) |
| micromolecular secretory switch | 4 (4) |
| nonproducer secretory switch | 4 (4) |
Abbreviations: ASCT—autologous stem-cell transplantation.